Wed, Jul 23, 2014, 12:56 AM EDT - U.S. Markets open in 8 hrs 34 mins

Recent

% | $
Click the to save as a favorite.

Allergan Inc. Message Board

  • pooping_bull pooping_bull Nov 27, 2012 1:22 PM Flag

    Seriscaffold

    Allergan bought this company 2 years ago. Don't see any sales data. Does anyone have a clue on this product line?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • AGN talked about this on the Conf Call in March.

      They are doing trials still.

      They hope to have entry into the market later in 2013 according to a Market Watch report I read in October.

      Not much to know about at this stage.

      Sentiment: Buy

    • There is not much to talk about. The last discussion by AGN was at the March Conf Call.

      If you go to Market Watch, you can find the following: type this header

      US Breast Implant Device Market to Continue Modest Growth, While European Market Remains Flat Through 2016

      In contrast to implants, the acellular dermal matrix segment has a significant number of competitors," said MRG Analyst Kristina Vidug. "Most of these companies also compete in the soft tissue repair device market, and leverage their existing brand identities when entering the breast implant device market. LifeCell is the largest competitor, with dominance in both allografts and xenografts. Allergan is expected to enter this segment with its SeriScaffold product in 2013.

      Sentiment: Strong Buy

    • This company was brought up for discussion in the March 2012 Conf Call. There is not much news ongoing. I know there are trials in progress:

      The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery

      They are recruiting people for more trials now.

      I know about this news in October:

      According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for breast implant devices will grow modestly, while the European market will remain essentially flat, with the combined total reaching a value of $1.1 billion by 2016. A new entrant into the US breast augmentation market may shake up what has been a stable, price-conscious market.

      Both the European and US breast implant markets are dominated by two multinational companies, Allergan and Mentor, with the rigorous Food and Drug Administration (FDA) approval process keeping others from entering the US market. Since the US represents 85 percent of the total implant market for the US and Europe, these companies are also dominant in Europe, making it difficult for smaller local companies to compete and gain market share.

      Competitors offer similar products with only differences in surface and shape, resulting in mainly a price competition. The stable duopoly of Allergan and Mentor will be changing, however. In 2012 Sientra received FDA approval for its highly cohesive "gummy bear" silicone implants. Sientra will be selling its implants at a premium price point, offering their products at a 15 to 20 percent price premium compared to traditional silicone implants. The company has also announced that it will be selling only to board-certified plastic surgeons, establishing a position as a high-quality, high-price product. The much smaller EU market saw breast implant device revenues (including reconstructions) decline by more than two percent from 2010 to 2011, and despite anticipated growth in 2015 and 2016, the European breast implant device market will see an average decline of one percent per year through 2016.

      "In contrast to implants, the acellular dermal matrix segment has a significant number of competitors," said MRG Analyst Kristina Vidug. "Most of these companies also compete in the soft tissue repair device market, and leverage their existing brand identities when entering the breast implant device market. LifeCell is the largest competitor, with dominance in both allografts and xenografts. Allergan is expected to enter this segment with its SeriScaffold product in 2013."

      Sentiment: Strong Buy

 
AGN
170.43-0.71(-0.41%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.